Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
about
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancersNurses transforming health care using genetics and genomicsSurvival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriersPublic health action in genomics is now needed beyond newborn screeningEvaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersUsing simulation to interpret a discrete time survival model in a complex biological system: fertility and lameness in dairy cowsCost of contralateral prophylactic mastectomyA simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian CancerUptake, time course, and predictors of risk-reducing surgeries in BRCA carriersCost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingSignificant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico.Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomyCost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancerRisk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancerCost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancerCurrent knowledge on contralateral prophylactic mastectomy among women with sporadic breast cancer.Online tool to guide decisions for BRCA1/2 mutation carriers.Is breast cancer prognosis inherited?Incorporating quality of evidence into decision analytic modeling.Hereditary ovarian cancer and two-compartment tumor metabolism: epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma.BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Prophylactic oophorectomy: a historical perspective.Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps.Individually tailored screening of breast cancer with genes, tumour phenotypes, clinical attributes, and conventional risk factors.American Society of Clinical Oncology policy statement on medicaid reform.Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.Economic Evaluation Alongside a Clinical Trial of Telephone Versus In-Person Genetic Counseling for BRCA1/2 Mutations in Geographically Underserved Areas.Economic evaluation of targeted cancer interventions: critical review and recommendations.Contralateral Prophylactic Mastectomy Consensus Statement from the American Society of Breast Surgeons: Additional Considerations and a Framework for Shared Decision Making.An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findingsEconomic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis.Quality assurance in medical and public health genetics services: a systematic review.The effect of a celebrity health disclosure on demand for health care: trends in BRCA testing and subsequent health services use.Cost effectiveness of pharmacogenomics: a critical and systematic review.Outcomes of genetic evaluation for hereditary cancer syndromes in unaffected individuals.Contralateral Prophylactic Mastectomy with Immediate Breast Reconstruction Increases Healthcare Utilization and Cost.
P2860
Q24611865-4B14A632-4E6A-446F-9866-3DAB9D841D4CQ24630531-987AD83F-0553-4CD2-BDD4-79291366C172Q24654487-C84165F5-60CB-41EF-82ED-3198E40E1A6BQ26998734-D8540843-837A-45DE-9D1E-DDCD8632F9BBQ33614244-9B8F4303-53FC-4D7E-BDD2-8207E080497CQ34015387-62DAA816-ECB6-446F-B61F-25ACB6B83CF1Q34017128-5099D6D2-1D43-4421-BCF4-C7DF4D83E498Q34097351-02ECAA30-2418-496A-BFFE-3883FECCE6DAQ34126089-0C68B90A-C0D2-4944-968F-7C7360AD88EEQ34152848-49295950-F81C-40F6-9BB6-EEC5A8125496Q34309892-84EA7F41-2404-4DB6-99DD-590A8138998FQ34994574-F1AA76E9-5124-4F01-A566-39D57E84012CQ35007651-1181A647-C042-4601-A781-9282654E9E7FQ35073191-F9E070F1-D422-4C85-A186-670C89F8705EQ35170200-77C23D26-9000-4961-83C2-8206D451B0D0Q35179515-785DA346-C405-4021-B526-2317F7AC2483Q35237983-60804B5A-D61E-4C6A-B17A-11CB6ABBECACQ35584662-6EDC18FA-F511-42A2-8D93-38246CFC06A7Q35808372-4E7728C7-2F7E-44FE-BC37-1519CCDF01D8Q35906350-2C515A23-A1A8-446F-B9A6-63706DE94610Q36285963-94EF6FB0-F392-4F0C-967E-D464B7B9F4ABQ36472233-71432035-55CC-4374-9090-3DE89590067BQ36556331-99974FE2-355F-4013-8CC6-A680BAEDA36CQ36738628-85CC70D1-2C18-4BEC-BC22-7D1804449985Q36746167-E03BA1E8-E7C0-4AE7-AA82-9597F5C46C29Q36917485-B944EDA8-49DE-4B6B-AC04-0DD9DF1D43DFQ36924790-5BA6E297-E7EE-4A70-A48B-39B355034751Q36934359-535E381E-4BA2-4509-BE18-B880B620AD3FQ36953155-B0C48D03-AAC2-4A9D-9CE1-92D1F157F069Q36973457-5950C723-9038-4D7A-AA9A-A33377746D37Q37125021-F4BFDCCC-67F4-45CB-B047-AAF9F38661EEQ37173971-8C8190D1-8DC2-48A0-A4CD-5A3D96B4C5ECQ37208201-6B885E3D-0D3A-4D15-8E5E-C4C0F727272BQ37260040-3D469001-635F-450C-BAFC-9016B669A0BEQ37315305-B3C37A96-EE88-4F4C-BAF9-1E3B019FB74AQ37557502-5DC4E99C-BF21-4FE7-AD54-76DDE1F5A249Q37746657-04175333-EE97-4654-82FF-CA53F5989156Q37799352-EC022B7B-B45E-4F87-B453-DD8698226AC3Q38253213-4D05AC53-3F17-4F0C-A5A6-EF1150784BB7Q38647477-3B9B9EA6-64C6-4433-B212-015923A1FBE0
P2860
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@en
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@nl
type
label
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@en
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@nl
prefLabel
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@en
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@nl
P2093
P1476
Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
@en
P2093
Alfred I Neugut
Daniel F Heitjan
Joshua Graff Zivin
Judith S Jacobson
Kristin Anderson
Victor R Grann
P304
P356
10.7326/0003-4819-144-6-200603210-00006
P407
P577
2006-03-01T00:00:00Z